

Metabolic profiling of Shu-Yu capsule in rat serum based on metabolic fingerprinting analysis using HPLC-ESI-MSⁿ

FANG LI^{1*}, YOU-BO ZHANG^{2*}, XIA WEI³, CHUN-HONG SONG⁴, MING-QI QIAO⁴ and HUI-YUN ZHANG⁴

¹Hospital Pharmacy, Fengtai Maternal and Children's Health Hospital of Beijing, Beijing 100069;

²State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines,

School of Pharmaceutical Sciences, Peking University Health Science Center, Peking University, Beijing 100101;

³Department of Pharmacology and Toxicology, Shandong Institute for Food and Drug Control, Jinan, Shandong 250012;

⁴Institute of Traditional Chinese Medicine Theory, School of Basic Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 100044, P.R. China

Received April 19, 2015; Accepted March 7, 2016

DOI: 10.3892/mmr.2016.5082

Abstract. The Chinese herbal formula, Shu-Yu capsule (SYC), has been successfully used to treat depression-like disorders in clinical settings. To rapidly identify the chemical constituents of SYC and its metabolites in rat serum, a simple and sensitive liquid chromatography-tandem mass spectrometry method was established in the present study. By comparing the retention times, MS and MSⁿ spectra data in the literature and reference standards, a total of 73 compounds were identified from SYC. In rat serum, 62 components, including 13 prototype compounds and 49 metabolites were identified. Of these components, 14 metabolites were confirmed as novel metabolites of SYC. The results of the present study indicated that certain flavonoid glycosides and monoterpene glycosides were absorbed directly. Glucuronidation and sulfation were identified as the predominant metabolic pathways of the components in SYC. In addition, certain phase I reactions, including hydrolysis, demethylation and hydroxylation occurred in the rats. These results provide scientific evidence,

which support further investigations of the pharmacology and mechanism of SYC.

Introduction

The Shu-Yu capsule (SYC) formulation is a four-herb traditional Chinese medicine (TCM) used for the treatment of clinical depression-like disorders, including premenstrual syndrome (1). It is composed of four herbal ingredients: Radix Bupleuri (*Bupleurum chinense* DC.), Radix Paeoniae Alba (*Paeonia lactiflora* Pall.), Rhizoma Cyperi (*Cyperus rotundus* Linn.) and Radix Glycyrrhizae (*Glycyrrhiza uralensis* Fisch.). According to the TCM formulation theory (2), Radix Bupleuri and Radix Paeoniae Alba are mutually complementary as the monarch herbs of the formula, which represent the components with the major therapeutic roles.

It has been demonstrated that the total glycosides of peony exert significant antidepressant-like effects by increasing the expression levels of brain derived neurotrophic factor and nerve growth factor in selective brain tissues (3). Radix Bupleuri is another monarch ingredient in SYC, which may affect the quality of prescriptions significantly. Bupleuri Radix, or prescriptions containing Bupleuri Radix as the major component, for example Xiaochaihutang, exert antidepressant-like effects by modulating serotonergic and noradrenergic systems in brain regions of rat models of depression (4,5). Our previous studies also revealed antidepressant-like effects of ethanol extracts from *Paeonia lactiflora* Radix and Bupleuri Radix (6). These findings confirmed that Paeoniae Radix and Bupleuri Radix have effects on the central nervous system. According to the theory of serum pharmacology, only constituents absorbed into blood have the potential to exert pharmacological bioactivities (7). However, the metabolites absorbed in the blood following oral administration of SYC remain to be elucidated.

The present study aimed to confirm the absorbed components and the relative metabolites of SYC, which may be the potential bioactive components in the blood following intragastric administration of SYC. Thus, a reliable high performance liquid chromatography-electrospray ionization tandem mass

Correspondence to: Professor Ming-Qi Qiao or Professor Hui-Yun Zhang, Institute of Traditional Chinese Medicine Theory, School of Basic Medicine, Shandong University of Traditional Chinese Medicine, Changqing University Science and Technology Park, 4655 University Road, Changqing, Jinan, Shandong 100044, P.R. China

E-mail: qmingqi@163.com

E-mail: zhuiyun@163.com

*Contributed equally

Abbreviations: SYC, Shu-Yu capsule; TCM, traditional Chinese medicine; HPLC-ESI-MSⁿ, high performance liquid chromatography-electrospray ionization tandem mass spectrometry

Key words: Shu-Yu capsule, chemical constituents, absorption, high performance liquid chromatography-electrospray ionization tandem mass spectrometry, metabolites

spectrometry (HPLC-ESI-MSⁿ) system was established for the detection of prototype compounds and metabolites in the rat serum following oral administration of SYC. Screening for potential bioactive components in SYC may assist in future investigations into its mechanism of action at the molecular level.

Materials and methods

Reagents. Acetonitrile, methanol and glacial acetic acid were of LC/MS reagent grade and purchased from Merck Millipore (Darmstadt, Germany), Ultra-pure water was prepared using a Milli-Q water purification system (EMD Millipore, Bedford, MA, USA). The other solvents were of analytical grade.

Radix Bupleuri, Radix Paeoniae, Radix Glycyrrhizae and Rhizoma Cyperi were collected in Shandong Province (Shandong, China) and were authenticated by Professor Hui Yun Zhang (Shandong University of Traditional Chinese Medicine, Jinan, China). SYCs were manufactured by Qingdao Haichuan Innovative Biological & Natural Drug Research Institute (Qingdao, China).

The composition and preparation of the SYC were as previously described (1).

Instrument and analysis conditions. The HPLC analysis was performed on an Agilent-1100 series liquid chromatograph system (Agilent Technologies, Inc., Santa Clara, CA, USA), equipped with a binary pump, an auto sampler, a photo-diode array detector and a column temperature controller. The analytical column was a Kromasil C18 100R (5 μ m, 250x4.6 mm i.d.; AkzoNobel, Bohus, Sweden) and the oven temperature was maintained at 25°C. A mobile phase, composed of eluent A (acetonitrile) and B (0.2% acetic acid in water, v/v) with a gradient was used for the separation. The elution conditions were applied with the following linear gradient: 0-5 min, 2-5% A; 5-12 min, 5-12% A; 12-28 min, 12-16% A; 28-42 min, 16-24% A; 42-56 min, 24-36% A; 56-72 min, 36-39% A; 72-81 min, 39-64% A; 81-90 min and 64-100% A. The flow rate was 1.0 ml/min and peaks were detected at 254 nm.

In the subsequent ESI-MS/MS experiment, an MSD Trap XCT Plus mass spectrometer (Agilent Technologies) was connected to the same HPLC instrument via an electrospray ionization (ESI) interface (Agilent Technologies, Inc.). The HPLC effluent was introduced into the ESI source in a post-column splitting ratio of 1:4. The ESI-MS operating conditions (negative ion) were optimized using the SYC, as follows: Nebulizer gas pressure, 40.00 psi; dry gas flow rate, 11.00 l/min; capillary temperature, 350°C; electrospray voltage of the ion source, 3,500 V; skimmer of 40.0 V; capillary exit, 121.0 V; compound stability, 50%; trap drive level, 100%; target mass, 500 m/z; scan range, 100-14,00 m/z; collision energy, 1 V. A data-dependent program was used for the HPLC-ESI-MSⁿ analysis, to enable the protonated or deprotonated ions to be selected for further MSⁿ analysis. An Agilent 6300 Series Trap Control workstation (version 6.1; Agilent Technologies, Inc.) was used for data processing.

Preparation of samples for the extract. Sample preparation of the SYC was as follows: A single capsule from each of five

batches of SYC were used. The powder-like contents of the capsules were mixed evenly, and 0.3 g of the mixed powder was weighed. The Radix Paeoniae, Radix Bupleuri, Rhizoma Cyperi and Radix Glycyrrhizae samples were crushed into a homogeneous size separately and sieved through a No. 40 mesh sieve (Jin Yuan Screen Factory, Yangquan, China) for further assessment.

The weighed powder was suspended in 25.0 ml of 70% (v/v) methanol and extracted in an ultrasonic water bath for 30 min at room temperature. Each resulting mixture was filtered through 0.22- μ m membranes prior to use, and a 10- μ l aliquot was injected into the HPLC-MS system for analysis.

In-vivo experiments. A total of 24 male Wistar rats (weight, 180-220 g; age, 8 weeks) were supplied by the Laboratory Animal Center of Shandong University of Traditional Chinese Medicine. The present study was approved by the Institutional Committee for Animal Care and Use of Shandong University of Traditional Chinese Medicine. The rats were housed in poly cages with free access to food and water, at a temperature of 22-26°C and relative humidity of 50-70%. The rats were acclimatized to the environment for 1 week prior to initiating the experiment. All rats were fasted, with free access to water, for 12 h prior to the experiment. Subsequently, 12 rats were administered with SYC at a dose of 4.1 g/kg body weight orally for 3 days, once per day. Another group of 12 rats served as a blank control group, which received physiological saline. On day 4, blood samples were collected from the inferior vena cava, 90 min after intragastric administration of SYC, and centrifuged at 1,500 x g for 15 min at 4°C to obtain serum samples, which were then frozen and stored at -80°C until analysis. Subsequently, the rats were sacrificed by cervical dislocation. The time points were selected based on our previous pharmacokinetic studies (8). All procedures were in agreement with the National Institute of Health's Guidelines on the Principles of Animal Care (9).

Sample preparation. The dried powders from the SYCs and the four herbs were weighed accurately (0.3 g), suspended in 25.0 ml of 70% (v/v) methanol, and extracted in an ultrasonic water bath (KQ-250E; Kunshan Ultrasonic Instruments Co., Ltd.) for 30 min at room temperature. Each resulting mixture was filtered through 0.22 μ m polyvinylidene fluoride membranes (Merck Millipore) prior to use, and a 10 μ l aliquot was injected into the HPLC-MS system for analysis.

Each collected serum sample was thawed and centrifuged at 1,500 x g for 30 min at 4°C. The supernatant (100 μ l) was then mixed with 300 μ l methanol and vortexed for 2 min. The denatured protein precipitate was separated by centrifugation at 16,000 x g for 30 min at 4°C, and the supernatant was separated and evaporated to dryness under a gentle nitrogen stream at 37°C. The residue was reconstituted in 100 μ l methanol and centrifuged at 16,000 x g for 30 min at 4°C. An aliquot of 20 μ l of the supernatant was analyzed on the HPLC-MS system.

Results

HPLC-MSⁿ analysis of constituents in SYC extract in negative ion mode. Utilizing the optimized LC-MSⁿ method, the components of the extracts of SYC and its single herbal extracts

Table I. Identification of the chemical constituents of SYC formula by liquid chromatography-tandem mass spectrometry in negative ion mode.

No.	t _R ^a	[M-H] ⁻ (m/z)	MS ⁿ (m/z)	Identification	Source	Molecular formula
1	3.1	341	179, 161, 143, 119, 113	Caffeic acid-4-O-β-D-glucopyranoside	RG	C ₁₅ H ₁₈ O ₉
2 ^b	4.8	191	111, 173, 129	Quinic acid	RG	C ₇ H ₁₂ O ₆
3 ^b	6.9	375	345, 165	Desbenzoylpaeoniflorin	RP	C ₁₆ H ₂₄ O ₁₀
4	9.3	169	125	Gallic acid	RP	C ₇ H ₆ O ₅
5	11.1	493	313, 331, 283, 169	1'-O-galloyl-sucrose	RP	C ₁₉ H ₂₆ O ₁₅
6	11.6	493	313, 331, 169	6'-O-galloyl-sucrose	RP	C ₁₉ H ₂₆ O ₁₅
7 ^b	15.0	527	497, 479, 271	6'-O-galloyldesbenzoylpaeoniflorin	RP	C ₂₃ H ₂₈ O ₁₄
8	15.8	705	543, 421, 375	Isomaltopaeoniflorin sulfonate	RP	C ₂₉ H ₃₈ O ₁₈ S
9 ^b	16.5	543	421, 375, 259, 497	Paeoniflorin sulfonate	RP	C ₂₃ H ₂₈ O ₁₃ S
10	16.8	495	465, 311, 137,	Oxypaeoniflorin	RP	C ₂₃ H ₂₈ O ₁₂
11	17.9	495	465, 333, 137	Oxypaeoniflorin or isomer	RP	C ₂₃ H ₂₈ O ₁₂
12	19.4	525	495, 167, 465, 509	Mudanpioside E	RP	C ₂₄ H ₃₀ O ₁₃
13	21.4	701 ^e	641, 519, 611, 489	Isomaltopaeoniflorin	RP	C ₂₉ H ₃₈ O ₁₆
14	23.2	641	519, 489, 475, 611	6'-O-d-glucopyranosylalbiflorin	RP	C ₂₉ H ₁₈ O ₁₆
15	24.3	701 ^e	611, 593, 641, 489, 471	Isomaltopaeoniflorin	RP	C ₂₉ H ₃₈ O ₁₆
16 ^{b,c}	24.7	539 ^e	479, 357, 327, 283	Albiflorin	RP	C ₂₃ H ₂₈ O ₁₁
17	27.6	495	465, 311, 137	Ortho-Oxypaeoniflorin	RP	C ₂₃ H ₂₈ O ₁₂
18 ^{b,c,d}	27.8	539 ^e	479, 449, 327, 165	Paeoniflorin	RP	C ₂₃ H ₂₈ O ₁₁
19	28.7	539 ^e	449, 479, 327, 165	Paeoniflorin isomer	RP	C ₂₃ H ₂₈ O ₁₁
20	33.9	787	635, 483, 465, 617, 313	Tetragalloylglucose	RP	C ₃₄ H ₂₈ O ₂₂
21	34.5	787	635, 465, 483, 617, 313	Tetragalloylglucose or isomer	RP	C ₃₄ H ₂₈ O ₂₂
22	34.7	577	457, 503, 383	Isoviolanthin	RG	C ₂₇ H ₃₀ O ₁₄
23 ^b	35.2	549	255, 417, 135, 429	Liquiritin apioside	RG	C ₂₆ H ₃₀ O ₁₃
24	35.3	417	255, 135, 153, 119	Neoliquiritin	RG	C ₂₁ H ₂₂ O ₉
25 ^b	35.7	453	417, 135, 255	Hydrated Liquiritin	RG	C ₂₁ H ₂₆ O ₁₁
26 ^b	35.9	417	255, 135, 153, 119	Liquiritin	RG	C ₂₁ H ₂₂ O ₉
27	36.5	539 ^e	479, 357, 327, 449	Albiflorin or isomer	RP	C ₂₃ H ₂₈ O ₁₁
28 ^b	39.0	631	613, 491, 479, 465, 313	Galloyl paeoniflorin/Galloylalbiflorin	RP	C ₃₀ H ₃₂ O ₁₅
29	39.5	939	769, 617, 447, 601, 599	Pentagalloylglucose	RP	C ₄₁ H ₃₂ O ₂₆
30 ^b	42.0	631	313, 509, 465, 169	Galloylpaeoniflorin/Galloylalbiflorin	RP	C ₃₀ H ₃₂ O ₁₅
31	44.0	433	271, 151	Naringenin-O-glucose	RG	C ₂₁ H ₂₂ O ₁₀
32	45.3	479	357, 327	Isopaeoniflorin/Albiflorin R ₁	RP	C ₂₃ H ₂₈ O ₁₁
33	45.7	479	357, 397, 327, 283, 337	Isopaeoniflorin/Albiflorin R ₁	RP	C ₂₃ H ₂₈ O ₁₁
34	46.1	647	525, 479	Benzoylpaeoniflorin sulfonate	RP	C ₃₀ H ₃₂ O ₁₄ S
35	46.6	647	525, 479	Benzoylpaeoniflorin Sulfonate or isomer	RP	C ₃₀ H ₃₂ O ₁₄ S
36	47.1	549	255, 417, 429, 135	Isoliquiritin apioside	RG	C ₂₆ H ₃₀ O ₁₃
37 ^b	47.6	445	269, 251	Apigenin-7-O-β-D-glucuronide	RB	C ₂₁ H ₁₈ O ₁₁
38	48.0	445	269, 175	Baicalin	RB	C ₂₁ H ₁₈ O ₁₁
39	48.2	631	465, 509, 313, 613, 169	Galloylpaeoniflorin or isomer	RP	C ₃₀ H ₃₂ O ₁₅
40	48.5	417	255, 135, 153, 119	Isoliquiritin	RG	C ₂₁ H ₂₂ O ₉
41	48.9	417	255, 135, 119, 153	Neoisoliquiritin	RG	C ₂₁ H ₂₂ O ₉
42	49.6	647	617, 525	Benzoylpaeoniflorin Sulfonate/isomer	RP	C ₃₀ H ₃₂ O ₁₄ S
43	49.5	417	255, 135, 119, 153	Neoisoliquiritin/isomer	RG	C ₂₁ H ₂₂ O ₉
44	49.7	255	135, 153, 119	Liquiritigenin	RG	C ₁₅ H ₁₂ O ₄
45	50.0	695	549, 531, 255	Licorice-glycoside B	RG	C ₃₅ H ₃₆ O ₁₅
46	50.2	725	549, 531, 255	Licorice-glycoside A	RG	C ₃₆ H ₃₈ O ₁₆
47	50.6	285	269	Kaempferol	RB	C ₁₅ H ₁₀ O ₆
48	52.1	255	135, 153, 119	Liquiritigenin/isomer	RG	C ₁₅ H ₁₂ O ₄
49	52.3	459	283, 268, 175	Wogonoside	RB	C ₂₂ H ₂₀ O ₁₁

Table I. Continued.

No.	t _R ^a	[M-H] ⁻ (m/z)	MS ⁿ (m/z)	Identification	Source	Molecular formula
50 ^b	54.4	459	283, 268	Wogonoside/isomer	RB	C ₂₂ H ₂₀ O ₁₁
51	54.8	521 ^c	461, 163, 265	Lactiflorin	RP	C ₂₃ H ₂₆ O ₁₀
52	55.3	521 ^c	461, 163	Lactiflorin/isomer	RP	C ₂₃ H ₂₆ O ₁₀
53	57.5	643 ^c	583, 553, 431, 165	Benzoylpaeoniflorin	RP	C ₃₀ H ₃₂ O ₁₂
54	57.6	553	431, 165	Dehydroxylate Demethylene Benzoylpaeoniflorin	RP	C ₂₉ H ₃₀ O ₁₁
55	58.4	643 ^c	583, 461, 553	Isobenzoylpaeoniflorin	RP	C ₃₀ H ₃₂ O ₁₂
56	59.2	271	151, 119	Naringenin	RG	C ₁₅ H ₁₂ O ₅
57	61.5	837	351, 193, 661, 819	Licorice-saponin G2	RG	C ₄₂ H ₆₂ O ₁₇
58	62.1	819	351, 193, 643, 801	Licorice-saponin E ₂	RG	C ₄₂ H ₆₀ O ₁₆
59	65.1	255	135, 153, 119	Isoliquiritigenin	RG	C ₁₅ H ₁₂ O ₄
60	65.4	811	649, 471, 439	SSb ₃ or SSb ₄	RB	C ₄₃ H ₇₂ O ₁₄
61	65.5	821	645, 469, 351, 193	Glycyrrhizin	RG	C ₄₂ H ₆₂ O ₁₆
62	66.3	821	645, 351, 193	Uralsaponin A	RG	C ₄₂ H ₆₂ O ₁₆
63	66.8	267	252	Formononetin	RG	C ₁₆ H ₁₂ O ₄
64 ^d	71.9	779	617, 471, 541, 439, 423	SSa	RB	C ₄₂ H ₆₈ O ₁₃
65 ^d	72.4	779	617, 471, 541, 439	SSd	RB	C ₄₂ H ₆₈ O ₁₃
66	72.7	367	309, 297, 352	Glycycoumarin	RG	C ₂₁ H ₂₀ O ₆
67	76.5	283	268	Wogonin	RB	C ₁₆ H ₁₂ O ₅
68	77.3	677 ^c	617, 471, 541, 439	Prosaikogenin G/F	RB	C ₃₆ H ₅₈ O ₈
69	77.7	677 ^c	617, 471, 541, 407	Prosaikogenin A/D	RB	C ₃₆ H ₅₈ O ₈
70	80.4	367	309, 281, 297, 265	Glycycoumarin/isomer	RG	C ₂₁ H ₂₀ O ₆
71	82.0	353	297	Licoisoflavone A	RG	C ₂₀ H ₁₈ O ₆
72	83.0	353	297	Licoisoflavone A/isomer	RG	C ₂₀ H ₁₈ O ₆
73	83.3	381	366	licoricone	RG	C ₂₂ H ₂₂ O ₆

^at_R, retention time; ^babsorbed compounds detected in dosed rat serum; ^cabsorbed compounds detected in dosed rat brain; ^didentified by comparison with standards; ^esolvent adduct ion [M-H+CH₃COOH]⁻; RP, radix paeoniae alba; RG, radix glycyrrhizae; RB, radix bupleuri. SS, saikosaponin; MS, mass spectrometry.

(Radix Paeoniae Alba, Radix Bupleuri, Radix Glycyrrhizae and Rhizoma Cyperi) were identified.

By comparing the MSⁿ spectra data with the reference standards and literature data, 73 components, including flavonoids, terpenes and phenolic acids, were identified in the SYC extract. Among these 73 components, three predominant compounds were confirmed using reference standards. The HPLC-MSⁿ data of the 73 tentatively identified components are summarized in Table I.

By comparing the chromatograms and MSⁿ data between the extracts of SYC and the single herb extracts, the 73 identified components originated predominantly from Radix Bupleuri, Radix Paeoniae Alba and Radix Glycyrrhizae. In the SYC extracts, 34 compounds belonging to monoterpene glycosides, galloylglucoses and phenolic compounds were identified as being derived from Radix Paeoniae. In addition, 11 compounds belonging to flavonoids and triterpene glycosides were identified as ingredients of Radix Bupleuri, and 28 compounds were derived from Radix Glycyrrhizae. The identity of each component was confirmed by matching the empirical molecular formula with that of previously published information, and was further elucidated using multistage mass

spectrometry, particularly for the unmatchable components in the in-house library. In addition, certain data, including retention time (t_R), were also included as complementary data for identification. Acetic acid was added to the mobile phase as a modifier, and its adduct ions [M-H+CH₃COOH]⁻ were observed in the mass spectra of certain components.

Identification of the components of SYC from Radix Paeoniae.

In the present study, a total of 34 compounds were identified in the extracts of SYC from Radix Paeoniae. For compound 16 (t_R=24.7 min), the solvent adduct ion [M-H+CH₃COOH]⁻ at 539 m/z was observed, and the featured fragmentation ions at 283, 327, 357 and 479 m/z were produced, consistent with the data reported in the literature (10). Compound 18 (t_R=27.8 min) was identified as paeoniflorin by comparison with reference compounds, and produced the featured fragmentation ions at 165, 327 and 449 m/z, consistent with the data reported in the literature (10). Compounds 19 (t_R=28.7 min) and 27 (t_R=36.5 min) were induced as an isomer of albiflorin and paeoniflorin, respectively, due to a series of common characteristic ions (Table I). Compounds 32 (t_R=45.3 min) and 33 (t_R=45.7 min) were identified as isopaeoniflorin

and albiflorin R₁, sharing the molecular formula C₂₃H₂₈O₁₁, according to literature references (11). Compounds 10 (tR=16.8 min), 11 (tR=17.9 min) and 17 (tR=27.6 min) were deduced as oxypaeoniflorin/oxypaeoniflorin isomer and ortho-oxypaeoniflorin (10), respectively, considering that oxypaeoniflorin exhibits a higher polarity than ortho-oxypaeoniflorin; and their ions in common at 495 m/z, 465 m/z ([M-H-HCHO]⁻) and 137 m/z ([C₇H₅O₃]⁻). Compound 12 (tR=19.4 min) gave [M-H]⁻ ions at m/z 525 (C₂₄H₃₀O₁₃) and further produced an [M-H-OCH₃]⁻ ion at 495 m/z and an [M-H-OCH₃-CH₂OH]⁻ ion at 465 m/z. Therefore, this species was tentatively identified as mudanpioside E, according to its structure reported in the literature (12).

The two isomer compounds, 51 (tR=54.8 min) and 52 (tR=55.3 min) (13), revealed the solvent adduct ion [M-H+CH₃COOH]⁻ at 521 m/z, the protonated molecular ion [M-H]⁻ at 461 m/z and the ion at 265 m/z, which was produced via the neutral losses of CO₂ (44 Da), HCHO (30 Da) and benzoyl acid (BA, 122 Da) from the precursor ion. Therefore, compound 51,52 was tentatively identified as lactiflorin or an isomer.

Compounds 53 (tR=57.5 min) and 55 (tR=58.4 min) were tentatively assigned as benzoylpaeoniflorin and isobenzoylpaeoniflorin (11) by the solvent adduct ion [M-H+CH₃COOH]⁻ at 643 m/z and the protonated molecular ion [M-H]⁻ at 583 m/z, which further loses a benzoyl group (122 Da) to produce the ion [M-H-122]⁻ at 461 m/z and at 553 m/z, and further loses a benzoyl group (122 Da) to produce the ion [M-H-HCHO-122]⁻ at 431 m/z. Compound 54 may be the secondary product of benzoylpaeoniflorin in the plant due to the same [M-H]⁻ at 553, 431 and 165 m/z as compound 55. Therefore, compound 54 was identified as dehydroxylate demethylene benzoylpaeoniflorin.

Compound 3 (tR=6.9 min) exhibited the [M-H]⁻ ion at 375 m/z, and then produced the ion [M-H-HCHO]⁻ at 345 m/z in the negative full scan mode. A further fragment at 165 m/z suggested the existence of a glucosyl group. Therefore, compound 3 was tentatively identified as desbenzoylpaeoniflorin, according to the literature and its fragmentation pathway (10). Compound 7 (tR=15.0 min) produced the ion [M-H]⁻ at 527 m/z in the MS spectrum and product ion [M-H-HCHO]⁻ at 497 m/z in the MS/MS spectrum. The MS³ spectral ions at 479 m/z ([M-H-HCHO-H₂O]⁻) and 271 m/z were observed. And the ion at 271 m/z may have been produced by the losses of galloyl radicals (152 Da), 2HCHO (30 Da) and CO₂ (44 Da). Therefore, compound 7 was confirmed as 6'-O-galloyldesbenzoylpaeoniflorin. Compounds 28 (tR=39.0 min), 30 (tR=42.0 min) and 39 (tR=48.2 min) exhibited the [M-H]⁻ ion at 631 m/z. Considering the common fragmentation ions at 613, 465, 313 and 169 m/z, these three components were assigned as galloylpaeoniflorin (14,15), galloylablbfiflorin or their isomers; and this was consistent with the literature (10). Compounds 13 (tR=21.4 min) and 15 (tR=24.3 min) were two isomers with the solvent adduct ion [M-H+CH₃COOH]⁻ at 701 m/z. Compound 14 (tR=23.2 min) produced [M-H]⁻ at 641 m/z. In addition, these compounds yielded a series of common ions, including [M-H-HCHO]⁻ at 611 m/z, [M-H-H₂O-HCHO]⁻ at 593 m/z, [M-H-BA]⁻ at 519 m/z and [M-H-HCHO-BA]⁻ at 489 m/z. By referring to the literature, compounds 13, 15 and

14 were identified as isomaltopaeoniflorin or isomers, and 6'-O-d-glucopyranosylalbiflorin (16).

Compounds 5 (tR=11.07 min) and 6 (tR=11.64 min) produced fragmentation ions at 313 m/z [M-H-170]⁻, 331 m/z [M-H-152]⁻ and 169 m/z [gallic acid]⁻. Their fragment ions indicated the loss of the gallic acid moiety (170 Da) and/or galloyl radicals (152 Da) from the precursors of [M-H]⁻; thus these two compounds were assigned as 1'-O-galloylsucrose, 6'-O-galloylsucrose. For compounds 19 (tR=33.9 min) and 20 (tR=34.5 min), fragmentation ions at 787 m/z [M-H]⁻, 617 m/z [M-H-170]⁻, 635 m/z [M-H-152]⁻, 483 m/z [M-H-2galloyl]⁻ and 465 m/z [M-H-2galloyl-H₂O]⁻ were produced in negative ion mode. Compounds 19 and 20 were tentatively identified as tetragalloylglucose or an isomer. Similarly, compound 29 was tentatively deduced as pentagalloylglucose, according to the fragmentation pathway and data in the literature (17). However, their structures were not elucidated from the MS data due to limited information regarding the linkage position of the galloyl groups relative to the glucose unit.

Compounds 8 (tR=15.8 min), 9 (tR=16.5 min), 34 (tR=46.1 min), 35 (tR=46.6 min) and 42 (tR=49.6 min) were detected and matched with the data in the literature (10), revealing that they were identical to those of isomaltopaeoniflorin sulfonate, paeoniflorin sulfonate, benzoylpaeoniflorin sulfonate or their isomers.

Identification of the components of SYC derived from Radix Bupleuri. A total of six flavonoids, including baicalin, wogonoside, wogonin, apigenin-7-O-β-D-glucuronide and kaempferol or their isomers, were detected in the SYC extracts derived from Radix Bupleuri. Compounds 37 (tR=47.6 min) and 38 (tR=48.0 min) provided common [M-H]⁻ ions at 445 m/z and the MS/MS ion [M-H-gluconic acid]⁻ at 269 m/z. However, they exhibited different typical major ions at 251 m/z ([M-H-gluconic acid-H₂O]⁻) and 175 m/z, respectively. Therefore, compound 38 was deduced as baicalin (16), and compound 37 was deduced as apigenin-7-O-β-D-glucuronide. Similarly, compounds 49 (tR=52.3 min) and 50 (tR=54.4 min) produced [M-H]⁻ ions at 459 m/z, the MS² ion at 283 m/z, corresponding to [M-H-gluconic acid]⁻, and the MS³ ion at 268 m/z, corresponding to [M-H-gluconic-acid-CH₃]⁻. Accordingly, compounds 49,50 was tentatively identified as wogonoside or an isomer (16). Also, compound 67 (tR=76.5 min) was identified as wogonin, showing the [M-H]⁻ ion at 283 m/z and the [M-H-CH₃]⁻ ion at 268 m/z (18). Another flavonoid had the characteristic fragment ion at 285 m/z ([M-H]⁻) and 269 m/z ([M-H-OH]⁻), therefore, compound 47 was identified as kaempferol.

A total of five saikosaponins (SSs) from the SYC extracts were identified or tentatively identified in the negative-ion ESI mode, among which two SSs, including SSa (compound 64; tR=71.9 min) and SSd (compound 65; tR=72.4 min) were identified through comparison of their tR, and MSn data with those of the reference substances. Compound 60 (tR=65.4 min) produced the [M-H]⁻ species at 811 m/z, and further produced the [M-H-Glc]⁻ ion at 649 m/z and the [M-H-FucGlc-CH₃OH]⁻ ion at 471 m/z, and was tentatively identified as SS₃ or SS₄ (16). Compound 68 (tR=77.3 min) and compound 69 (tR=77.7 min) shared the solvent adduct ion [M-H+CH₃COOH]⁻ at 677 m/z; and the common fragmentation ions were determined at




Figure 1. Suggested fragmentation pathways for compounds 68 and 69.

617 m/z ($[M-H]^-$), 541 m/z , corresponding to $[M-H-C_3H_8O_2]^-$ and 471 m/z , corresponding to $[M-H-Fuc]^-$. In addition, for compound 68, 439 m/z (corresponding to $[M-H-Fuc-CH_3OH]^-$), was its additional fragmentation ion; and for compound 69, 407 m/z ($[M-H-Fuc-OH-CH_2O-H_2O]^-$) was its additional fragmentation ion. According to the common and additional fragmentation ions, compound 68 was tentatively deduced as prosaikogenin G or prosaikogenin F, and compound 69 was identified as prosaikogenin A or prosaikogenin D (19). The structure of compound 68/69 and the possible fragmentation patterns are summarized in Fig. 1. In addition, compounds 68 and 69 were possible secondary metabolites of the SSs in the plants during processing, storage or long-distance transport (20).

Identification of the components of SYC from Radix Glycyrrhizae. A total of 28 compounds, including flavanones, isoflavanones, coumarins and saponins were detected in the

SYC extracts derived from *Radix Glycyrrhizae*. Compounds 24 ($tR=35.3$ min), 26 ($tR=35.9$ min), 40 ($tR=48.5$ min), 41 ($tR=48.9$ min) and 43 ($tR=49.5$ min) exhibited the same $[M-H]^-$ ion at 417 m/z . The fragment ion at 255 m/z was observed by loss of a glucose residue (162 Da). The alycone ion at 255 m/z was then further fragmented to the product ion at 153, 135 or 119 m/z through Retro-Diels-Alder (RDA) cleavage. Thus, compounds 24, 26, 40, 41 and 43 were tentatively identified as neoliquiritin, liquiritin, isoliquiritin, neoisoliquiritin and neoisoliquiritin isomer (21).

The two isomeric compounds 23 ($tR=35.2$ min) and 36 ($tR=47.1$ min) exhibited identical MS data in the negative ion mode. With the exception of the same $[M-H]^-$ ion at 549 m/z , their MS/MS spectra exhibited $[M-H-xyl]^-$ at 417 m/z $[M-H-xyl-glc]^-$ at 255 m/z , and the product ion at 135 or 119 m/z . Thus, compound 23 was deduced as liquiritin apioside and compound 36 was tentatively identified as isoliquiritin apioside. Compound 25 ($tR=35.7$ min) shared




Figure 2. Suggested fragmentation pathway for compounds 66 and 70.

a series of characteristic ions at 417, 255 and 135 m/z with liquiritin, and its molecular weight was 36 D higher than that of liquiritin, indicating that compound 25 was hydrated liquiritin.

The three isomeric compounds 44 ($tR=49.7$ min), 48 ($tR=52.1$ min) and 59 ($tR=65.1$ min) produced the same ion $[M-H]^-$ at 255 m/z , which was further fragmented to the product ion at 135, 153 or 119 m/z via the RDA reaction (22). Thus, compounds 44, 48 and 59 were identified as liquiritigenin, liquiritigenin isomer and isoliquiritigenin. Compounds 45 ($tR=50.0$ min) and 46 ($tR=50.2$ min) showed $[M-H]^-$ ions at 695 and 725 m/z . The two compounds exhibited the common product ion at 549, 531 and 255 m/z . In the MS/MS spectrum, compounds 45 and 46 produced $[M-H\text{-rhamnosyl}]^-$ and $[M-H-176]^-$ at 549 m/z , respectively. They subsequently produced the MS^3 ion at 255 m/z by losing a glucose residue (162 Da) and an apiose residue (132 Da). Therefore, compounds 45 and 46 were identified as licorice-glycoside B and licorice-glycoside A (22).

Compound 22 ($tR=34.70$ min) exhibited $[M-H]^-$ at 577 m/z . In the MS/MS spectrum, the $[M-H-120]^-$ ion at 457 m/z , the $[M-H-74]^-$ ion at 503 m/z and the $[M-H-120-74]^-$ ion at 383 m/z suggested flavone C-glucosides, and these produced typical losses of 120 Da from the precursor ions; and the flavone C-rhamnosides generated the product ions by losing 74 Da. Compound 22 was deduced to be isoviolanthin (22). Compound 63 ($tR=66.8$ min) was identified as formononetin, according to the $[M-H]^-$ ion at 267 m/z and the $[M-H-CH_3]^-$ ion at 252 m/z .

The two isomeric compounds 71 ($tR=82.0$ min) and 72 ($tR=83.0$ min) exhibited the $[M-H]^-$ ion at 353 m/z , corresponding to the product ion at 297 m/z ; therefore, they were identified as licoisoflavone A or an isomer, according to the literature (23). In addition, compound 73 ($tR=83.3$ min) exhibited the $[M-H]^-$ ion at 381 m/z , corresponding to the product ion at 366 m/z in the MS/MS spectra. Thus, compound 73 was deduced as licoricone.

Compounds 57 ($tR=61.5$ min) and 58 ($tR=62.1$ min) exhibited the deprotonated molecule $[M-H]^-$ ion at 837 and

819 m/z , respectively. The $[M-H]^-$ ion of the two compounds fragmented into two products at 351 m/z ($[glucuroglucuronic\ acid-H]^-$) and 193 m/z ($[glucuronic\ acid-H]^-$). Furthermore the $[M-H\text{-gluA}]^-$ ion and the $[M-H\text{-H}_2O]^-$ ion were also detected in the MS/MS spectra of the two compounds. Based upon the above fragmentation pattern and previous literature (22), compounds 57 and 58 were identified as licorice-saponin G2 and licorice-saponin E2. Compounds 61 ($tR=65.5$ min) and 62 ($tR=66.3$ min) generated $[M-H]^-$ at 821 m/z in the negative ion mode. The $[M-H]^-$ ion fragmented into two characteristic ions at 645 and 469 m/z , which corresponded to $[M-H\text{-glucuronic\ acid}]^-$ and $[M-H\text{-di-glucuronic\ acid}]^-$, respectively. Therefore, compounds 61 and 62 were identified as glycyrrhizin and ursalaponin A, according to the literature (22).

Only two coumarins were present in SYC, and these were identified as glycosylcoumarin. Compounds 66 ($tR=72.7$ min) and 70 ($tR=80.4$ min) exhibited the $[M-H]^-$ ion at 367 m/z , and the MS/MS spectrum produced the $[M-H-CH_3]^-$ ion at 352 m/z , $[M-H-CH_3-C_3H_7]^-$ ion at 309 m/z and $[M-H-CH_3-C_4H_9]^-$ ion at 297 m/z . The C_3H_7 and C_4H_9 fragment ions corresponded to an isopentenyl residue. The further loss of an oxhydryl group generated an ion at 281 m/z . Compounds 66 and 70 were then identified as glycosylcoumarin (24). The fragmentation pathway of glycosylcoumarin is shown in Fig. 2.

Compound 56 ($tR=59.2$ min) exhibited the $[M-H]^-$ ion at 271 m/z , and produced two major product ions at 151 m/z ($[C_7H_3O_4]^-$) and 119 m/z ($[C_8H_7O]^-$), in agreement with the classic 1,3A- and 1,3B- fragments. This indicated the presence of two and one hydroxyl groups substituted on rings A and B of a flavanone, respectively, further confirming the identity of compound 56 as naringenin, a known compound in *Glycyrrhizae Radix et Rhizoma* (25). Compound 31 ($tR=44.0$ min) exhibited the deprotonated molecule $[M-H]^-$ at 433 m/z and produced predominant fragment ions at 271 m/z $[M-H\text{-glc}]^-$ in the MS^2 spectra and MS^3 ions at 151 and 119 m/z , which was in accordance with the fragmentation pattern of naringenin. Therefore, compound 31 was deduced as naringenin-O-glucose (26).

Table II. MS and MSⁿ data of the identified metabolites absorbed in rat serum following oral administration of SYC in negative mode.

No.	t _R ^a	Formula	[M-H] ⁻ (m/z)	MS ⁿ (m/z)	Possible original compound	Identification
M1 ⁿ	5.6	C ₂₂ H ₂₆ O ₁₁	465	345, 165, 327	Paeoniflorin	Dehydroxylate Demethylene oxypaeoniflorin
M2	7.2	C ₉ H ₁₀ O ₇ S	261	215, 171	Catechin-associated	3, 4-Dihydroxy phenylpropionic acid sulfate
M3 ⁿ	14.0	C ₂₂ H ₃₀ O ₁₆	549	373, 197, 175	Paeoniflorin	PaeonimetabolinIdi-glucuronide
M4	14.1	C ₈ H ₈ O ₈ S	263	183, 167	Gallic acid-associated	4-O-Methyl gallic acid sulfate or 3-O- Methyl gallic acid sulfate
M5	16.5	C ₂₃ H ₂₈ O ₁₃ S	543	421, 375, 259, 497	Paeoniflorin	Paeoniflorin sulfonate
M6	18.1	C ₇ H ₆ O ₇ S	233	189	Gallic acid-associated	Protocatechuic acid-4-O-sulfate
M7	19.8	C ₂₇ H ₃₀ O ₁₅	593	417, 255	Flavonoid-associated	liquiritin glucuronide
M8 ⁿ	20.3	C ₂₂ H ₃₀ O ₁₆	549	373, 197, 175	Paeoniflorin	PaeonimetabolinIdi-glucuronide
M9	22.0	C ₁₅ H ₁₈ O ₁₁	373	197, 175	Paeoniflorin	PaeonimetabolinIglucuronide
M10	24.0	C ₉ H ₈ O ₆ S	243	163	Catechin-associated	m-Coumaric acid sulfate
M11	24.5	C ₇ H ₆ O ₇ S	233	189	Gallic acid-associated	Protocatechuic acid-3-O-sulfate
M12 ⁿ	26.8	C ₁₇ H ₂₄ O ₁₀	387	211, 197, 175	Gallic acid-associated	Trimethyl gallic acid glucuronide
M13 ⁿ	27.8	C ₂₂ H ₂₀ O ₁₁	459	283, 267	Flavonoid-associated	Formononetin hydroxylate glucuronide or isomer
M14 ⁿ	29.1	C ₂₂ H ₂₆ O ₁₀	569Δ	449, 327, 539, 509	Paeoniflorin	methyl hydroxylate paeoniflorin
M15 ⁿ	32.1	C ₂₁ H ₂₈ O ₁₃	487	311, 267	Flavonoid-associated	Di-methyl-formononetin hydroxylate glucuronide
M16	34.3	C ₂₆ H ₂₆ O ₁₂	529	353, 175	Flavonoid-associated	Licoisoflavone A glucuronide
M17	34.7	C ₂₁ H ₂₀ O ₁₀	431	255, 175, 135, 119	Flavonoid-associated	Liquiritigenin-4, -O-glucuronide
M18	35.3	C ₂₁ H ₂₀ O ₁₀	431	255, 175, 135	Flavonoid-associated	Liquiritigenin-7-O-glucuronide
M19	35.7	C ₁₀ H ₁₂ O ₈ S	291	211, 197	Gallic acid-associated	Di-methyl C ₈ H ₈ O ₈ S
M20	36.1	C ₂₁ H ₂₀ O ₁₀	431	255, 175, 135	Flavonoid-associated	Isoliquiritigenin-4-O-glucuronide
M21	36.7	C ₂₁ H ₂₀ O ₁₀	431	255, 175	Flavonoid-associated	Isoliquiritigenin-7-O-glucuronide
M22	37.3	C ₂₁ H ₂₀ O ₁₁	447	271, 151	Flavonoid-associated	Naringenin glucuronide
M23	39.9	C ₇ H ₆ O ₇ S	233	189	Gallic acid-associated	Protocatechuic acid-3-O-sulfate
M24	41.6	C ₂₇ H ₃₂ O ₁₄	579	271, 151	Flavonoid-associated	Naringenin-O-rutinoside
M25	42.4	C ₁₃ H ₁₄ O ₈	297	175, 113	Gallic acid-associated	Benzoyl glucuronide
M26	42.8	C ₁₄ H ₁₆ O ₁₄ S	439	263, 121	Gallic acid-associated	C ₈ H ₈ O ₈ S glucuronide
M27	43.1	C ₂₆ H ₂₆ O ₁₂	529	353, 175	Flavonoid-associated	Na Licoisoflavone A glucuronide
M28	43.3	C ₉ H ₁₀ O ₈ S	277	197, 169	Gallic acid-associated	3,4-Di-O-methyl gallic acid sulfate
M29	43.9	C ₂₁ H ₂₀ O ₁₁	447	271, 151	Flavonoid-associated	Naringenin glucuronide
M30	44.5	C ₂₇ H ₃₀ O ₁₆	609	301, 286, 242	Flavonoid-associated	Hesperidin
M31	45.7	C ₁₅ H ₁₂ O ₇ S	335	255, 135, 119	Flavonoid-associated	Liquiritigenin-4, -O-sulfate
M32	45.9	C ₁₅ H ₁₂ O ₇ S	335	255, 135, 119	Flavonoid-associated	Liquiritigenin-7-O-sulfate
M33	46.7	C ₁₇ H ₂₂ O ₁₁	401	225	Uncertain	Methyl propyl gallate glucuronide
M34 ⁿ	49.0	C ₂₃ H ₂₂ O ₁₁	473	297, 253	Flavonoid-associated	Methyl formononetin hydroxylate glucuronide
M35	50.3	C ₂₁ H ₂₀ O ₁₀	431	255, 135, 119, 175	Flavonoid-associated	Isoliquiritigenin glucuronide isomer
M36 ⁿ	50.4	C ₁₅ H ₁₈ O ₁₁	453	277, 233	Gallic acid-associated	C ₉ H ₁₀ O ₅ glucuronide
M37	51.1	C ₁₇ H ₁₂ O ₈	343	229, 165, 149	Ellagic acid	3,7,8-Trimethyl ellagic acid
M38	51.3	C ₂₁ H ₂₂ O ₁₃	433	257, 175	Flavonoid-associated	Davidigenin glucuronide
M39	51.5	C ₁₇ H ₁₂ O ₈	343	229, 149, 165	Ellagic acid	3,7,8-Trimethyl ellagic acid
M40 ⁿ	52.1	C ₃₀ H ₄₈ O ₃	455	437	Saponin-associated	Saikogenin B
M41	54.8	C ₂₂ H ₂₄ O ₁₅ S	559	515, 383, 339	Coumarin-associated	Glycycoumarin hydroxylate glucuronide
M42 ⁿ	54.9	C ₂₂ H ₂₀ O ₁₁	459	283, 267	Flavonoid-associated	Formononetin hydroxylate glucuronide or isomer

Table II. Continued.

No.	t _R ^a	Formula	[M-H] ⁻ (m/z)	MS ⁿ (m/z)	Possible original compound	Identification
M43	56.6	C ₁₆ H ₁₂ O ₇ S	347	267, 252	Flavonoid-associated	Formononetin sulfate
M44	57.0	C ₁₆ H ₁₂ O ₇ S	347	267, 252	Flavonoid-associated	Formononetin sulfate
M45 ⁿ	58.3	C ₂₆ H ₂₈ O ₁₁	515	353	Flavonoid-associated	Licoisoflavone A glucose
M46 ⁿ	61.3	C ₁₅ H ₂₂ O ₉	405 ^b	345, 327	Paeoniflorin	Dehydroxylate Demethylene desbenzoylpaeoniflorin
M47 ⁿ	61.4	C ₁₅ H ₂₂ O ₉	405 ^b	345, 327	Paeoniflorin	Dehydroxylate Demethylene desbenzoylpaeoniflorin
M48	67.0	C ₁₆ H ₁₄ O ₉	349	303, 287	Flavonoid-associated	Dihydroxyl methyl quercetin -chalcone
M49	71.6	C ₂₁ H ₂₀ O ₉ S	447	367	Coumarin-associated	Glycycoumarin sulfate

^at_R, retention time; ^bsolvent adduct ion [M-H+CH₃COOH]⁻; n, novel metabolites of certain constituents of SYC; SYC, Shu-Yu capsule; MS, mass spectrometry.

Identification of the absorbed components in rat serum following oral administration of SYC extracts. The absorbed components and metabolites were difficult to elucidate due to their low concentrations. In order to improve the detection sensitivity, extracted ion chromatograms (EICs) were used. First, the protonated molecular ions in Table I were used one by one to obtain EICs from the dosed rat serum, blank rat serum and SYC extract simultaneously. Subsequently, by comparing these obtained EICs, components that appeared in the dosed rat serum and SYC extract, but not in the blank rat serum, were considered to be the components absorbed into serum in the prototype. Once these components were determined as the absorbed components, they were further confirmed by carefully comparing their MS, MSⁿ data and retention times with those in Table I. As a result, 13 prototype compounds were absorbed into the rat serum in the prototype and identified as quinic acid, desbenzoylpaeoniflorin, 6'-O-galloyl-desbenzoylpaeoniflorin paeoniflorin sulfonate, albiflorin, paeoniflorin, liquiritin apioside, liquiritin, hydrated-liquiritin, galloylpaeoniflorin, galloylalbiflorin, apigenin-7-O-β-D-glucuronide and wogonoside.

Identification of the metabolites from rat serum following oral administration of SYC. Drug metabolism involves two types of enzyme-catalyzed reactions, phase I and phase II. Phase I metabolism includes oxidation, reduction, hydroxylation and desaturation; phase II metabolism includes glucuronidation, sulfation and glutathione conjugation, which may occur directly on the parent compounds, which contain appropriate structural motifs, or, as is usually the case, on functional groups added or exposed by phase I oxidation. These results increase the solubility of the drug metabolites in water, causing them to be more easily excreted from the body (27). In the present study, sulfation, glucuronidation and methylation were detected as the predominant phase II reactions, and the oxidation reaction and demethylation were observed as the predominant phase I reactions. In general, 49 compounds were considered as metabolites of SYC (Table II), in which 14 metabolites were confirmed as novel compounds.

Identification of gallic acid-associated metabolites. In the present study, a total of 10 compounds were identified as metabolites of gallic acid or polyphenols, which can be degraded into gallic acid in the body. The possible metabolic pathways of gallic acid and the associated compounds are presented in Fig. 3.

M4 exhibited the [M-H]⁻ ion at 263 m/z, which yielded the MS/MS ion at 183 m/z with a loss of 80 Da (SO₃), and the MS³ ion at 167 m/z, suggesting that gallic acid underwent the sulfation and methylation reactions. Therefore, M4 was tentatively identified as 4-O-methyl gallic acid sulfate or 3-O-methyl gallic acid sulfate. M26 exhibited the [M-H]⁻ ion at 439 m/z and yielded the product ions at 263 m/z, corresponding to a loss of 176 Da. Thus, M26 was tentatively identified as C₈H₈O₈S glucuronide. M28 showed an [M-H]⁻ ion at 277 m/z, the product ion at 197 m/z and the MS³ ion at 169 m/z with a loss of 28 Da via the MS² spectrum, suggesting that M28 was a sulfate conjugate of dimethyl gallic acid. In addition, M19 exhibited the [M-H]⁻ ion at 291 m/z, which is 28 Da higher than M4, and the product ion at 211 m/z with a loss of 80 Da (SO₃), suggesting that they were sulfate conjugates, indicating that M19 was the dimethyl conjugate of M4. M36 exhibited the [M-H]⁻ ion at 453 m/z and the product ion at 277 m/z with a loss of 176 Da, indicating that M36 was the glucuronide conjugate of M28.

M6 and M11 exhibited an [M-H]⁻ ion at 233 m/z, which produced product ions at 189 and 153 m/z, suggesting that they were sulfate conjugates. Thus, M6 was determined as protocatechuic acid-4-sulfate, whereas M11 was identified as protocatechuic acid-3-sulfate, with reference to previous reports (15). M12 exhibited the [M-H]⁻ ion at 387 m/z and yielded product ions at 211, 197 and 175 m/z, indicating that M12 was a glucuronide conjugate of the three methylation products of gallic acid. M25 exhibited the [M-H]⁻ ion at 297 m/z and the product ion at 121 m/z with a loss of 176 Da, indicating that M25 was the glucuronide conjugate of benzoic acid.

Identification of paeoniflorin-associated metabolites. In the present study, a total of eight compounds detected in

the rat serum were tentatively assigned as metabolites originating from paeoniflorin, which may also be the metabolites of other paeoniflorin-associated compounds, including desbenzoylpaeoniflorin or oxypaeoniflorin. With the exception of M5 (paeoniflorin sulfonate) and M9 (paeonimetalin glucuronide), the other six metabolites were identified for the first time as metabolites of paeoniflorin. The suggested metabolic pathways for paeoniflorin are shown in Fig. 4.

M9 exhibited the MS² spectra [aglycon-H]⁻ and [glucuronyl-H]⁻ at 197 and 175 m/z, and we tentatively assigned as paeonimetalin I glucuronides. M3 and M8 shared with M9 a series of characteristic ions at 175, 197 and 373 m/z. In addition, M3 and M8 were 176 Da higher than M9. Thus, M3 and M8 were assigned as glucuronide conjugates of M9.

Paeoniflorin sulfate absorbed M5 into the serum, and may be the metabolite of paeoniflorin through sulfation *in vivo*. A proportion of the paeoniflorin sulfate was most likely absorbed into the rat serum in the prototype from the SYC extract.

M14 exhibited the solvent adduct ion [M-H+CH₃COOH]⁻ at 569 m/z and shared the same characteristic ions at 165, 327, 449 and 479 m/z with paeoniflorin. In addition, compared with the molecular weight of paeoniflorin, these other species were 30 Da higher via methylation and hydroxylation reactions. Thus M14 was tentatively identified as methyl hydroxylate paeoniflorin. M1, M46 and M47 shared the same MS/MS fragmentation ion at 345 m/z and a further fragmentation ion at 327 m/z with a loss of 18 Da. In addition, M46 and M47 exhibited the solvent adduct ion [M-H+CH₃COOH]⁻ at 405 m/z, and M1 exhibited the deprotonated ion [M-H]⁻ at 465 m/z. Based on the information presented above, M1 was tentatively identified as dehydroxylate demethylene oxypaeoniflorin. M46/M47 was tentatively identified as dehydroxylate demethylene desbenzoylpaeoniflorin or its isomer.

Identification of flavonoid-associated metabolites. A total of 19 compounds were identified as metabolites originating from dihydroflavone, flavanones and isoflavonoids, including liquiritin, kaempferol, licoisoflavone A and formononetin. Their LC-MSⁿ data are summarized in Table II, and the possible metabolic pathways of liquiritin are presented in Figs. 5 and 6.

Liquiritin was first metabolized into its aglycone liquiritigenin, and liquiritigenin was then conjugated with glucuronide and sulfate. Isomerization into chalcones was also common for liquiritin. The present study revealed that M7, M17, M18, M31 and M32 were detected as major metabolites of liquiritin; and M20, M21, M38 and M35 were assigned as major metabolites of isoliquiritin. M17, M18, M20, M21 and M35 exhibited identical protonated molecules at 431 m/z, which produced identical product ions at 255, 135 and 119 m/z with a loss of 176 Da, indicating that they may be the glucuronide conjugates of liquiritigenin and isoliquiritigenin. However, the corresponding retention times differed markedly. According to the literature (23), the present study tentatively identified M17 and M18 as liquiritigenin-4'-O-glucuronide and liquiritigenin-7-O-glucuronide, respectively; and another three metabolites were identified as the glucuronide conjugates of isoliquiritigenin. Further investigation is required to determine the detailed structure of the metabolites of isoliquiritigenin.

Based on the characteristic neutral loss of 80 Da and previous information (28), M31 and M32 were tentatively identified as liquiritigenin-4-O-sulfate and liquiritigenin-7-O-sulfate, respectively.

M7 exhibited the [M-H]⁻ ion at 593 m/z, which further lost a glucuronic acid moiety (176 Da) to produce the ion at 417 m/z [M-H-176]⁻ and 255 m/z [M-H-176-162]⁻, indicating that M8 was the glucuronide conjugate of liquiritin. M38 exhibited the [M-H]⁻ ion at 433 m/z and the further product ion at 257 m/z [M-H-176]⁻ and 175 m/z, suggesting it to be the glucuronide conjugate of daidigenin.

Formononetin has been well documented to be metabolized to daidzein (29), which is 14 Da (CH₂) less than the protonated ion of formononetin. In the present study, daidzein was then conjugated with methylate, hydroxylate, sulfate and glucuronide. M13 and M42 exhibited the [M-H]⁻ ion at 459 m/z, the MS² ion at 283 m/z and the MS³ ion at 267 m/z, with a loss of 16 Da, compared with the MS² ion. The MS² ion was 176 Da less than the protonated ion of M13 and M42. Therefore, M13/M42 was assigned as formononetin hydroxylate glucuronide or its isomer. M43 and M48 had the same neutral loss of 80 Da in the negative ion mass spectrum, indicating that they were the sulfated conjugates of formononetin or isomers. M15 and M34 were identified as glucuronide conjugates due to the characteristic neutral loss of 176 Da (glucuronic acid). The MS² ion at 311 m/z of M15 and the MS² ion at 297 m/z of M34 were 44 and 30 Da higher, compared with the weight of formononetin, respectively, indicating that M15 and M34 may be formononetin or daidzein following methylation and hydroxylation. Therefore, M15 and M34 were identified as di-methyl-formononetin hydroxylate glucuronide and methyl formononetin hydroxylate glucuronide, respectively. The possible metabolic pathways of the formononetin-associated compounds are presented in Fig. 6.

M16 and M27 produced fragment ions at 529 and 353 m/z, corresponding to a loss of 176 Da. Therefore, they were tentatively identified as glucuronide conjugates of licoisoflavone A. M45 exhibited the [M-H]⁻ ion at 515 m/z and the product ion at 353 m/z with a loss of 162 Da (glucose-H₂O). Thus, M45 was identified as licoisoflavone A glucose.

M24 exhibited the [M-H]⁻ ion at 579 m/z, and M22 and M29 exhibited the [M-H]⁻ ion at 447 m/z; and they exhibited the same fragment ion, at 271 and 151 m/z, as naringenin. Their MS/MS spectra produced the [M-H-308]⁻ ion at 271 m/z of M24, and the [M-H-176]⁻ ion at 271 m/z of M22 and M29. Therefore, M24 was tentatively identified as naringenin-7-rutinoside, and M22, M29 was tentatively identified as naringenin-7-O-glucuronide or naringenin-4'-O-glucuronide. M30 exhibited the [M-H]⁻ ion at 609 m/z, the MS² ion [M-H-308]⁻ ion at 301 m/z and the MS³ ion [M-H-308-CH₃]⁻ ion at 286 m/z, which were consistent with previous reports (30). Therefore, M30 was tentatively identified as hesperidin. M48 exhibited the [M-H]⁻ ion at 349 m/z, the [M-H-CH₂O₂]⁻ ion at 303 m/z in the MS² spectrum and the [M-H-CH₂O₂-OH]⁻ ion at 287 m/z in the MS³ spectrum, indicating that M48 may be the metabolite of the parent compound, quercetin. As a result, M48 was identified as dihydroxyl methyl quercetin-chalcone.

Identification of saponin-associated metabolites. M40 exhibited an [M-H]⁻ ion at 455 m/z, which produced a




Figure 3. Suggested metabolic pathways of gallic acid-associated metabolites following oral administration with Shu-Yu capsule.




Figure 4. Suggested metabolic pathways of paeoniflorin-associated metabolites following oral administration with Shu-Yu capsule.




Figure 5. Suggested metabolic pathway of liquiritin following oral administration with Shu-Yu capsule.




Figure 6. Suggested metabolic pathways of formononetin following oral administration with Shu-Yu capsule.

product ion at 437 *m/z* with a loss of 18 Da. Consistent with the literature (20), the heteroannular and the homoannular saikogenins showed different characteristic fragment ions of

the deprotonated molecules, including the ions [M-H-H₂O]⁻, [M-H-CH₃OH]⁻ or [M-H-CH₂O-H₂O]⁻. In addition, the fragmentations observed at [M-H-H₂O]⁻ were most abundant for

SGH (471 m/z) and SGB (455 m/z), [M-H-CH₃OH]⁻ for SGD (471 m/z) and [M-H-CH₂O-H₂O] for SGA (471 m/z) and SGC (455 m/z) in the negative ion MS/MS spectra. Therefore, the M40 metabolite was characterized as SGB.

Identification of coumarin-associated metabolites. M41 produced a [M-H]⁻ ion at 559 m/z, which produced a product ion at 383 m/z with a loss of 176 Da, indicating that M41 was a glucuronide conjugate. In addition, the product ion at 383 m/z was 16 Da higher, compared with that of the molecular weight of glycycomarin, which was tentatively assigned to hydroxylation reactions of glycycomarin. Thus, M41 was identified as glycycomarin hydroxylate glucuronide, which corroborates results from the literature (31).

M49 yielded a [M-H]⁻ ion at 447 m/z, which produced a product ion at 367 m/z with a loss of 80 Da (SO₃), indicating that M49 was a sulfate conjugate of glycycomarin, according to the literature (31). Thus, M49 was tentatively identified as glycycomarin sulfate.

Discussion

In the present study, an HPLC-ESI-MSⁿ method was developed and applied to analyze the herbal components of SYC extracts, and the absorbed compounds and metabolites in rat serum following oral administration of SYC extracts. As a result, a total of 73 herbal components, including 28 monoterpenes, 26 flavonoids, 9 triterpenoids, 2 coumarins, and other phenolic compounds and galloyl glucoses were observed and tentatively identified. All the MSⁿ data from these compounds in SYC were consistent with previous literature for every herb (10,18). The compounds identified from the formulation provided information to support further investigation on the absorbed components and metabolites of SYC in rat serum.

The absorbed components and metabolites identified in the present study provide an overall understanding of the absorption and metabolism of SYC in the rat body. Flavonoids were the most abundant metabolites in the drug-containing serum, and a total of 28 flavonoids, including five parent compounds and 23 metabolites, were identified in the drug-containing serum. Monoterpene glycoside compounds were found to be another primary absorbed component, including seven parent compounds and eight metabolites in the dosed serum were found. A total of eight metabolites were produced from gallic acid-related compounds and two metabolites were produced from the coumarin derivatives. These results revealed that certain flavonoid glycosides and monoterpene glycosides were absorbed directly. Glucuronidation and sulfation were the predominant metabolic pathways of the components in SYC. In addition, it appeared that certain phase I reactions, including hydrolysis, demethylation and hydroxylation, also occurred.

Saponins are important in SYC, particularly the SSs, which were characterized with poor oral bioavailability. The majority of the SSs contained the unstable XIII, 28-oxide linkage, which may be hydrolyzed during extraction by organic acid or upon heating (32). Therefore, SSs exert curative effects by sequential deglycosylation metabolism in the intestine to form secondary glycoside and aglycones with improved pharmacological effects.

As is already known, TCM contains complex chemical constituents, which are directly absorbed into the blood, or indirectly absorbed via digestive intake or liver metabolism, and are then transported to target tissue through the circulation and exert effects on target tissue. The complexity and diversity of parent compounds and metabolites in the serum following the administration of TCM conforms to the theory of integrity and the synergistic effect of TCM, which is the material basis of the pharmacological actions. However, further investigations are required to clarify such pharmacological actions.

A simple and economical HPLC-ESI-MSⁿ method was established in the present study, and led to the first report, to the best of our knowledge, on the comprehensive determination of chemical constituents in SYC, as well as its metabolites in rat serum. The results of the present study provide a basis and theoretical foundation for clarification of the chemical composition and potential bioactive compounds of SYC. The results of the present study provided useful information for the further investigation of the pharmacology and mechanism of action of SYC.

Acknowledgements

This study was supported by a grant from the 973 Program of China (grant no. 2011CB-505100).

References

- Gao X, Sun P, Qiao M, Wei S, Xue L and Zhang H: Shu-Yu capsule, a traditional chinese medicine formulation, attenuates premenstrual syndrome depression induced by chronic stress constraint. *Mol Med Rep* 10: 2942-2948, 2014.
- Chen SL and Chen DX: Clinical application of combined use of Radix Bupleuri and Radix Paeoniae Alba. *Shanghai Journal of TCM* 41: 71-74, 2007 (In Chinese).
- Mao QQ, Xian YF, Ip SP, Tsai SH and Che CT: Long-term treatment with peony glycosides reverses chronic unpredictable mild stress-induced depressive-like behavior via increasing expression of neurotrophins in rat brain. *Behav Brain Res* 210: 171-177, 2010.
- Kwon S, Lee B, Kim M, Lee H, Park HJ and Hahm DH: Antidepressant-like effect of the methanolic extract from *Bupleurum falcatum* in the tail suspension test. *Prog Neuropsychopharmacol Biol Psychiatry* 34: 265-270, 2010.
- Su GY, Yang JY, Wang F, Ma J, Zhang K, Dong YX, Song SJ, Lu XM and Wu CF: Antidepressant-like effects of xiaochai-hutang in a rat model of chronic unpredictable mild stress. *J Ethnopharmacol* 152: 217-226, 2014.
- Song CH, Li F, Guo YH and Zhang HY: Effects of Shuyu capsule and its main composition on protein expression and function of CACNA1C in hippocampus of rat with PMS liver-qi stagnation. *Chinese Pharmacological Bulletin* 30: 1476-1477, 2014 (In Chinese).
- Wang XJ, Sun WJ, Sun H, Lv H, Wu Z, Wang P, Liu L and Cao H: Analysis of the constituents in the rat plasma after oral administration of Yin Chen Hao Tang by UPLC/Q-TOF-MS/MS. *J Pharm Biomed Anal* 46: 477-490, 2008.
- Ge QF: Effects of ShuYu capsule on the expression of 5-HT3 receptor and its signal pathway of 5-HTR3-Ca²⁺-CaM in rat hippocampus neurons. Master's degree thesis of Shandong University of Traditional Chinese Medicine: 32-33, 2012 (In Chinese).
- National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: The National Academies Press, 1996. doi:10.17226/5140.
- Li SL, Song JZ, Choi FF, Qiao CF, Zhou Y, Han QB and Xu HX: Chemical profiling of Radix Paeoniae evaluated by ultra-performance liquid chromatography/photo-diode-array/quadrupole time-of-flight mass spectrometry. *J Pharm Biomed Anal* 49: 253-266, 2009.

11. Braca A, Kiem PV, Yen PH, Nhiem NX, Quang TH, Cuong NX and Minh CV: New monoterpene glycosides from *Paeonia lactiflora*. *Fitoterapia* 79:117-120, 2008.
12. Lin HC; Ding HY, TW TS and Wu PL: Monoterpene glycosides from *Paeonia suffruticosa*. *Phytochemistry* 41: 237-242, 1996.
13. Su J, Zhang P, Zhang JJ, Qi XM, Wu YG and Shen JJ: Effects of total glucosides of peony on oxidative stress in the kidney from diabetic rats. *Phytomedicine* 17: 254-260, 2010.
14. Liang J, Xu F, Zhang YZ, Huang S, Zang XY, Zhao X, Zhang L, Shang MY, Yang DH, Wang X and Cai SQ: The profiling and identification of the absorbed constituents and metabolites of *Paeoniae Radix Rubra* decoction in rat plasma and urine by the HPLC-DAD-ESI-IT-TOF-MS(n) technique: A novel strategy for the systematic screening and identification of absorbed constituents and metabolites from traditional Chinese medicines. *J Pharm Biomed Anal* 83: 108-121, 2013.
15. Xiao S, Luo K, Wen X, Fan X and Cheng Y: A pre-classification strategy for identification of compounds in traditional Chinese medicine analogous formulas by high-performance liquid chromatography-Mass spectrometry. *J Pharm Biomed Anal* 92: 82-89, 2014.
16. Yang YY, Tang YZ, Fan CL, Luo HT, Guo PR and Chen JX: Identification and determination of the saikosaponins in *Radix bupleuri* by accelerated solvent extraction combined with rapid-resolution LC-MS. *J Sep Sci* 33: 1933-1945, 2010.
17. Chen L, Qi J, Chang YX, Zhu D and Yu B: Identification and determination of the major constituents in Traditional Chinese Medicinal formula Danggui-Shaoyao-San by HPLC-DAD-ESI-MS/MS. *J Pharm Biomed Anal* 50: 127-137, 2009.
18. Wang DD, Liang J, Yang WZ, Hou JJ, Yang M, Da J, Wang Y, Jiang BH, Liu X, Wu WY and Guo DA: HPLC/q TOF-MS-oriented characteristic components data set and chemometric analysis for the holistic quality control of complex TCM preparations: Niu Huang Shangqing pill as an example. *J Pharm Biomed Anal* 89: 130-141, 2014.
19. Bao Y, Li C, Shen H and Nan F: Determination of saikosaponin derivatives in *Radix bupleuri* and in pharmaceuticals of the chinese multiherb remedy xiaochaihu-tang using liquid chromatographic tandem mass spectrometry. *Anal Chem* 76: 4208-4216, 2004.
20. Liang Z, Oh K, Wang Y, Yi T, Chen H and Zhao Z: Cell type-specific qualitative and quantitative analysis of saikosaponins in three *Bupleurum* species using laser microdissection and liquid chromatography-quadrupole/time of flight-mass spectrometry. *J Pharm Biomed Anal* 97: 157-165, 2014.
21. Yan Y, Chai CZ, Wang DW, Yue XY, Zhu DN and Yu BY: HPLC-DAD-Q-TOF-MS/MS analysis and HPLC quantitation of chemical constituents in traditional Chinese medicinal formula Ge-Gen decoction. *J Pharm Biomed Anal* 80: 192-202, 2013.
22. Wang S, Chen L, Leng J, Chen P, Fan X and Cheng Y: Fragment ion diagnostic strategies for the comprehensive identification of chemical profile of Gui-Zhi-Tang by integrating high-resolution MS, multiple-stage MS and UV information. *J Pharm Biomed Anal* 98: 22-35, 2014.
23. Yan Z, Chen Y, Li T, Zhang J and Yang X: Identification of metabolites of Si-Ni-San, a traditional Chinese medicine formula, in rat plasma and urine using liquid chromatography/diode array detection/triple-quadrupole spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 885-886: 73-82, 2012.
24. Wang Y, He S, Cheng X, Lu Y, Zou Y and Zhang Q: UPLC-Q-TOF-MS/MS fingerprinting of traditional Chinese formula SiJunZiTang. *J Pharm Biomed Anal* 80: 24-33, 2013.
25. Xiang C, Qiao X, Ye M and Guo DA: Classification and distribution analysis of compounds in *Glycyrrhiza* using licorice compounds database. *Yao Xue Xue Bao* 47: 1023-1030, 2012 (In Chinese).
26. Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, Jiang Z, Ye M, Chu E and Cheng YC: Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). *J Chromatogr A* 1217: 5785-5793, 2010.
27. Holcapek M, Kolárová L and Nobilis M: High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites. *Anal Bioanal Chem* 391: 59-78, 2008.
28. Lu LL, Shu Y, Qian DW, Su SL, Duan JA, Qian YF and Xue CF: Identification of the metabolites of Sinisan extract in rat plasma, urine, feces and bile after intragastric administration. *Acta Pharm Sin* 46: 1374-1379, 2011 (In Chinese).
29. Tolleson WH, Doerge DR, Churchwell MI, Marques MM and Roberts DW: Metabolism of biochanin A and formononetin by human liver microsomes in vitro. *J Agric Food Chem* 50: 4783-4790, 2002.
30. Su ZH, Zou GA, Preiss A, Zhang HW and Zou ZM: Online identification of the antioxidant constituents of traditional Chinese medicine formula Chaihu-Shu-Gan-San by LC-LTQ-Orbitrap mass spectrometry and microplate spectrophotometer. *J Pharm Biomed Anal* 53: 454-461, 2010.
31. Qiao X, Ye M, Xiang C, Wang Q, Liu CF, Miao WJ and Guo DA: Analytical strategy to reveal the in vivo process of multi-component herbal medicine: A pharmacokinetic study of licorice using liquid chromatography coupled with triple quadrupole mass spectrometry. *J Chromatogr A* 1258: 84-93, 2012.
32. Huang HQ, Zhang X, Xu ZX, Su J, Yan SK and Zhang WD: Fast determination of saikosaponins in *Bupleurum* by rapid resolution liquid chromatography with evaporative light scattering detection. *J Pharm Biomed Anal* 49: 1048-1055, 2009.